Cargando…
Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
INTRODUCTION: Malignant cutaneous epithelial tumors comprise various skin malignancies originating from the cutaneous epithelium, including cutaneous squamous cell carcinoma, basal cell carcinoma, and malignant cutaneous adnexal tumors. Treatment options are limited, as the rarity of these tumors, e...
Autores principales: | Ishii, Maki, Hirai, Ikuko, Tanese, Keiji, Fusumae, Takayuki, Nakamura, Yoshio, Fukuda, Keitaro, Uchi, Hiroshi, Kabashima, Kenji, Otsuka, Atsushi, Yokota, Kenji, Yamazaki, Naoya, Namikawa, Kenjiro, Fujimura, Taku, Takenouchi, Tatsuya, Yamamoto, Yuki, Nishiguchi, Mana, Sato, Yasunori, Amagai, Masayuki, Funakoshi, Takeru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598805/ https://www.ncbi.nlm.nih.gov/pubmed/33126349 http://dx.doi.org/10.1097/MD.0000000000022913 |
Ejemplares similares
-
Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol
por: Hirai, Ikuko, et al.
Publicado: (2021) -
PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis
por: He, Runzhi, et al.
Publicado: (2022) -
Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol
por: Nakahara, Takeshi, et al.
Publicado: (2020) -
Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer
por: Tanese, Keiji, et al.
Publicado: (2019) -
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
por: Nakamura, Yoshio, et al.
Publicado: (2016)